C1 inhibitor, a multi-functional serine protease inhibitor

Summary

C1 inhibitor (C1INH) is a serpin that regulates both complement and contact (kallikrein-kinin) system activation. It consists of a serpin domain that is highly homologous to other serpins and an amino terminal non-serpin mucin-like domain. Deficiency of C1INH results in hereditary angioedema, a disease characterised by episodes of angioedema of the skin or the mucosa of the gastrointestinal tract or the oropharynx. Although early data suggested that angioedema was mediated via complement system activation, the preponderance of the data indicate that bradykinin is the mediator. In the past few years, it has become apparent that C1INH has additional anti-inflammatory functions independent of protease inhibition. These include interactions with leukocytes that may result in enhanced phagocytosis, with endothelial cells via Eand P-selectins that interfere with leukocyte rolling and in turn results in suppression of transmigration of leukocytes across the endothelium, and interactions with extracellular matrix components that may serve to concentrate C1INH at sites of inflammation. In addition, C1INH suppresses gram negative sepsis and endotoxin shock, partly via direct interaction with endotoxin that interferes with its interaction with macrophages, thereby suppressing tumour necrosis factor-α and other inflammatory mediators. C1INH treatment improves outcome in a number of disease models, including sepsis and other bacterial infections, possibly malaria, ischaemia-reperfusion injury (intestinal, hepatic, muscle, cardiac, brain), hyper-acute transplant rejection, and other inflammatory disease models. Recent data suggest that this effectiveness is the result of mechanisms that do not require protease inhibition, in addition to both complement and contact system activation.

Keywords

C1 inhibitor - complement - kallikrein-kinin system - sepsis - ischaemiareperfusion injury

• References

• 1 Lepow I, Ratnoff O, Rosen F. et al. Observations on a proesterase associated with partially purified first component of complement (C1). Proc Soc Exp Biol Med 1956; 92: 32.
• 2 Lepow I, Ratnoff O, Levy L. Studies on the activation of a proesterase associated with partially purified first component of human complement. J Exp Med 1958; 107: 451-74.
• 3 Ratnoff O, Lepow I. Some properties of an esterase derived from preparations of the first component of complement. J Exp Med 1957; 106: 327-343.
• 4 Coutinho M, Aulak KS, Davis IIIAE. Functional analysis of the serpin domain of C1 inhibitor. J Immunol 1994; 153: 3648-3654.
• 5 Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923-926.
• 6 Davis IIIA. C1 inhibitor and hereditary angioneurotic edema. Ann Rev Immunol 1988; 06: 595-628.
• 7 Davis III AE, Cai S, Liu D. The biological role of the C1 inhibitor in regulation of vascular permeability and modulation of inflammation. Adv Immunol 2004; 82: 331-363.
• 8 Schapira M, de Agostini A, Schifferli J. et al. Biochemistry and pathophysiology of human C1 inhibitor: Current issues. Complement 1985; 02: 111-126.
• 9 Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema. Am J Med 1963; 35: 37-44.
• 10 Landerman NS, Webster ME, Becker EL. et al. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 1962; 33: 330-341.
• 11 Austen KF, Sheffer AL. Detection of hereditary angioneurotic edema by demonstration of a profound reduction in the second component of human complement. New Engl J Med 1965; 272: 649-656.
• 12 Carpenter CB, Ruddy S, Shehadeh IH. et al. Complement metabolism in man: hypercatabolism of the fourth (C4) and third (C3) components in patients with renal allograft rejection and hereditary angioedema (HAE). J Clin Invest 1969; 48: 1495-1505.
• 13 Donaldson VH, Rosen FS. Action of complement in hereditary angioneurotic edema: the role of C‘1 esterase. J Clin Invest 1964; 43: 2204-2213.
• 14 Laurell AB, Lindegren J, Malmros I. et al. Enzymatic and immunochemical estimation of C1 esterase inhibitor in sera from patients with hereditary angioedema. Scand J Clin Lab Invest 1969; 24: 221-225.
• 15 Laurell AB, Martensson U, Sjoholm AG. C1 subcomponent complexes in normal and pathological sera studied by crossed immunoelectrophoresis. Acta Pathol Microbiol Scand 1976; 84: 455-464.
• 16 Curd JG, Prograis LJ, Cochrane CG. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J Exp Med 1980; 152: 742-747.
• 17 Schapira M, Silver LD, Scott CF. et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. New England Journal of Medicine 1983; 308: 1050-1053.
• 18 Berrettini M, Lammle B, White T. et al. Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood 1986; 68: 455-462.
• 19 Nussberger J, Cugno M, Amstutz C. et al. Plasma bradykinin in angio-oedema. Lancet 1998; 351: 1693-1697.
• 20 Donaldson V, Rosen F, Bing D. Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.). Trans Assoc Am Physicians 1977; 90: 174-183.
• 21 Donaldson VH, Ratnoff OD, Silva WDd. et al. Permeability-increasing activity in hereditary angioneurotic edema plasma. J Clin Invest 1969; 48: 642-653.
• 22 Ratnoff OD, Lepow IH. Complement as a mediator of inflammation. Enhancement of vascular permeability by purified C‘1 esterase. J Exp Med 1963; 118: 681-698.
• 23 Klemperer MR, Donaldson VH, Rosen FS. Effect of C‘1 esterase on vascular permeability in man: studies in normal and complement-deficient individuals and in patients with hereditary angioneurotic edema. J Clin Invest 1968; 47: 604-611.
• 24 Strang CJ, Auerbach KS, Rosen FS. C1s-induced vascular permeability in C2-deficient guinea pigs. J Immunol 1986; 137: 631-635.
• 25 Strang C, Cholin S, Spragg J. et al. Angioedema induced by a peptide derived from complement component C2. J Exp Med 1988; 168: 1685-1698.
• 26 Fields T, Ghebrewihet B, Kaplan A. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of spontaneous formation of bradykinin. J Allergy Clin Immunol 1983; 72: 54-60.
• 27 Curd JG, Yelvington M, Burridge N. et al. Generation of bradykinin during incubation of hereditary angioedema plasma. Mol Immunol 1982; 19: 1365 (Abstract).
• 28 Shoemaker LR, Schurman SJ, Donaldson VH. et al. Hereditary angioneurotic edema: Characterization of plasma kinin and vascular permeability-enhancing activities. Clin Exp Immunol 1994; 95: 22-28.
• 29 Wisnieski JJ, Knauss TC, Yike I. et al. Unique C1 inhibitor dysfunction in a kindred without angioedema. I. A mutant C1 inhibitor that inhibits C1s but not C1r. J Immunol 1994; 152: 3199-3209.
• 30 Zahedi R, Bissler JJ, Davis III AE. et al. Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-Val substitution and functional analysis of the recombinant mutant protein. J Clin Invest 1995; 95: 1299-1305.
• 31 Zahedi R, Wisnieski J, Davis IIIAE. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity. J Immunol 1997; 159: 983-988.
• 32 Han ED, MacFarlane RC, Mulligan AN. et al. Increased vascular permeability in C1 inhibitor-deficient mice is mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109: 1057-1063.
• 33 Cugno M, Zanichelli A, Foieni F. et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009; 15: 69-78.
• 34 Chang N-S, Boackle RJ, Leu RW. Characterization of C1 inhibitor binding to neutrophils. Immunology 1991; 73: 95-101.
• 35 Liu D, Lu F, Qin G. et al. C1 inhibitor-mediated protection from sepsis. J Immunol 2007; 179: 3966-3972.
• 36 Smith CW, Hollers JC, Bing DH. et al. Effects of human C1 inhibitor on complement-mediated human leukocyte chemotaxis. J Immunol 1975; 114: 216-220.
• 37 Cai S, Davis IIIAE. Complement regulatory protein C1 inhibitor binds to selec-tins and interferes with endothelial-leukocyte adhesion. J Immunol 2003; 171: 4786-4791.
• 38 Cai S, Dole V, Bergmeier W. et al. A direct role for C1 inhibitor in leukocyte adhesion. J Immunol 2005; 174: 6462-6466.
• 39 Bergamaschini L, Gatti S, Caccamo L. et al. C1 inhibitor potentiates the protective effect of organ preservation solution on endothelial cells during cold storage. Transplant Proc 2001; 33: 939-941.
• 40 Bergamaschini L, Gobbo G, Gatti S. et al. Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver. Clin Exp Immunol 2001; 126: 412-420.
• 41 Patston PA, Schapira M. Regulation of C1-inhibitor function by binding to type IV collagen and heparin. Biochem Biophys Res Commun 1997; 230: 597-601.
• 42 Hauert J, Patston PA, Schapira M. C1 inhibitor cross-linking by tissue transglutaminase. J Biol Chem 2000; 275: 14558-14562.
• 43 Jiang H, Wagner E, Zhang H. et al. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med 2001; 194: 1609-1616.
• 44 Bone RC. Gram-negative sepsis: a dilemma of modern medicine. Clin Microbiol Rev 1993; 06: 57-68.
• 45 Kalter ES, van Dijk WC, Timmerman A. et al. Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcal aureus. J Infect Dis 1983; 148: 682-691.
• 46 Morrison DC, Kline LF. Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharide (endotoxin). J Immunol 1977; 118: 362-368.
• 47 Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004; 04: 133-142.
• 48 Nuijens JH, Eerenberg-Belmer AJM, Huijbregts CCM. et al. Proteolytic inactivation of plasma C1 inhibitor in sepsis. J Clin Invest 1989; 84: 443-450.
• 49 Caliezi C, Wuillemin WA, Zeerleder S. et al. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2001; 52: 91-112.
• 50 Davis III AE, Cai S, Liu D. C1 inhibitor: Biologic activities that are independent of protease inhibition. Immunobiology 2007; 212: 313-323.
• 51 Davis III AE, Mejia P, Lu F. Biological activities of C1 inhibitor. Mol Immunol 2008; 45: 4057-4063.
• 52 Liu D, Cai S, Gu X. et al. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 2003; 171: 2594-2601.
• 53 Liu D, Cramer CC, Scafidi J. et al. N-linked glycosylation at Asn3 and the positively charged residues within the amino terminal domain of C1 inhibitor are required for its interaction with Salmonella typhimurium lipopolysaccharide and lipid A. Infect Immun 2005; 73: 4478-4487.
• 54 Liu D, Gu X, Scafidi J. et al. N-linked glycosylation is required for C1 inhibitor-mediated protection from endotoxin shock in mice. Infect Immun 2004; 72: 1946-1955.
• 55 Thorgersen EB, Ludviksen JD, Lambris JD. et al. Anti-inflammatory effects of C1-inhibitor in porcine and human whole blood are independent of its protease inhibition activity. Innate Immun 2010; 16: 254-264.
• 56 Marr N, Luu RA, Fernandez RC. Bordetella pertussis binds human C1 esterase inhibitor during the virulent phase, to evade complement-mediated killing. J Infect Dis 2007; 195: 58-588.
• 57 Lathem WW, Bergsbaken T, Welch RA. Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157: H7. J Exp Med 2004; 199: 1077-1087.
• 58 Lathem WW, Grys TE, Witowski SE. et al. StcE, a metalloprotease secreted by Escherichia coli O157: H7, specifically cleaves C1 esterase inhibitor. Mol Micro-biol 2002; 45: 277-288.
• 59 Mackintosh CL, Beeson JG, Marsh K. Clinical features and pathogenesis of severe malaria. Trends Parasitol 2004; 20: 597-603.
• 60 Schofield L, Grau GE. Immunological processes in malaria pathogenesis. Nat Rev Immunol 2005; 05: 722-735.
• 61 Caro HN, Sheikh NA, Taverne J. et al. Structural similarities among malarial toxins insulin second messengers, and bacterial endotoxin. Infect Immun 1996; 64: 3438-3441.
• 62 Bauernschmitt R, Bohrer H, Hagl S. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med 1998; 24: 635-638.
• 63 Fattouch K, Bianco G, Speziale G. et al. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reper-fusion: a randomized double-blind study. Eur J Cardiothorac Surg 2007; 32: 326-332.
• 64 Storini C, Rossi E, Marrella V. et al. C1-inhibitor protects against brain ischemiareperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol Dis 2005; 19: 10-17.
• 65 De Simoni MG, Rossi E, Storini C. et al. The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am J Pathol 2004; 164: 1857-1863.
• 66 Karpel-Massler G, Fleming SD, Kirschfink M. et al. Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. J Surg Res 2003; 115: 247-256.
• 67 Lauterbach M, Horstick G, Plum N. et al. C1-esterase inhibitor reverses functional consequences of superior mesenteric artery ischemia/reperfusion by limiting reperfusion injury and restoring microcirculatory perfusion. Shock 2007; 27: 75-83.
• 68 Lu F, Chauhan AK, Fernandes SM. et al. The effect of C1 inhibitor on intestinal ischemia and reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2005; 295: G1042-G1049.
• 69 Padilla ND, van Vliet AK, Schoots IG. et al. C-reactive protein and natural IgM antibodies are activators of complement in a rat model of intestinal ischemia and reperfusion. Surgery 2007; 142: 722-733.
• 70 Fiane AE, Videm V, Johansen HT. et al. C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pigto-human perfusion model. Immunopharmacology 1999; 42: 231-243.
• 71 Schelzig H, Simon F, Krischer C. et al. Ex-vivo hemoperfusion (eHPS) of pig-lungs with whole human blood: effects of complement inhibition with a soluble C1-esterase-inhibitor. Ann Transplant 2001; 06: 34-39.
• 72 Schroder C, Wu GS, Price E. et al. Hyperacute rejection of mouse lung by human blood: characterization of the model and the role of complement. Transplantation 2003; 76: 755-760.
• 73 Salvatierra A, Velasco F, Rodriguez M. et al. C1-esterase inhibitor prevents early pumonary dysfunction after lung transplantation in the dog. Am J Respir Crit Care Med 1997; 1997: 1147-1154.
• 74 Scherer M, Demertzis S, Langer F. et al. C1-esterase inhibitor reduces reperfusion injury after lung transplantation. Ann Thorac Surg 2002; 73: 233-239.
• 75 Marx G, Nashan B, Cobas Meyer M. et al. Septic shock after liver transplantation for Caroli’s disease: clinical improvement after treatment with C1-esterase inhibitor. Intensive Care Med 1999; 25: 1017-1020.
• 76 Struber M, Hagl C, Hirt SW. et al. C1-esterase inhibitor in graft failure after lung transplantation. Intensive Care Med 1999; 25: 1315-1318.
• 77 Lehmann TG, Heger M, Munch S. et al. In vivo microscopy reveals that complement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver. Transpl Int 2000; 13 (Suppl. 01) S547-550.
• 78 Klima U, Kutschka I, Warnecke G. et al. Improved right ventricular function after intracoronary administration of a C1 esterase inhibitor in a right heart transplantation model. Eur J Cardiothorac Surg 2000; 18: 321-327.
• 79 Ruud TE, Aasen AO, Pillgram-Larsen J. et al. Effects of peritoneal proteolysis and haemodynamics of prophylactic infusion with C1 inhibitor in experimental acute pancreatitis. J Gastroenterol 1986; 21: 1018-1024.
• 80 Yamaguchi H, Weidenbach H, Luhrs H. et al. Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis. Gut 1997; 40: 531-535.
• 81 Niederau C, Brinsa R, Niederau M. et al. Effects of C1-esterase inhibitor in three models of acute pancreatitis. Int J Pancreatol 1995; 17: 189-196.
• 82 Schneider DT, Nurnberger W, Stannigel H. et al. Adjuvant treatment of severe acute pancreatitis with C1 esterase inhibitor concentrate after haematopoietic stem cell transplantation. Gut 1999; 45: 733-736.
• 83 Testoni PA, Cicardi M, Bergamaschini L. et al. Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc 1995; 42: 301-305.
• 84 Henze U, Lennartz A, Hefemann B. et al. The influence of the C1-inhibitor BERINERT and the protein-free haemodialsate ACTIHAEMYL20% on the evolution of the depth of scald burns in a porcine model. Burns 1997; 23: 473-477.
• 85 Khorram-Sefat R, Goldmann C, Radke A. et al. The therapeutic effect of C1-inhibitor on gut-derived bacterial translocation after thermal injury. Shock 1998; 09: 101-108.
• 86 Radke A, Mottaghy K, Goldmann C. et al. C1 inhibitor prevents capillary leakage after thermal trauma. Crit Care Med 2000; 28: 3224-3232.
• 87 Lammle B, Zuraw BL, Heeb MJ. et al. Detection and quantitation of cleaved and un-cleaved high molecular weight kininogen in plasma by ligand blotting with radio-labeled plasma prekallikrein or factor XI. Thromb Haemost 1988; 59: 151-161.